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Cochrane Database, EMBASE and CINAHL electronic data-
bases. Studies included were published in the last decade, irre-
spective language that reported data on costs of adherence, non
adherence, or costs by adherence range. Two independent
researchers reviewed the titles and abstracts by disease. A tem-
plate was developed to extract data. Methodological issues were
compared both within and among each disease area. RESULTS:
A total of 145 full manuscripts were identiﬁed: 50 related to
diabetes, 52 to osteoporosis 43 to schizophrenia, and zero to
rheumatoid arthritis. Ten studies for diabetes, six for psychosis
and four for osteoporosis (20 total) were reviewed. Most studies
used cohort designs. Medication possession ratio was the most
common measure of compliance. There was signiﬁcant variation
in how outcomes were reported. Some non-compliance costs
were reported using 5%, 5%–25% and >25% thresholds of
non-compliance. Other studies reported total savings among
compliers, or differential medical charges between compliers and
non-compliers. Further, important differences were found in the
type of clinical and economic outcomes, window period, and
adjustment for confounders not only within disease-speciﬁc
studies but also across studies. CONCLUSIONS: There are sig-
niﬁcant methodological differences in studies of costs of non-
compliance in patients with chronic diseases. Readers should be
aware of those differences when comparing results of a speciﬁc
disease. Better and standardized methodology should be devel-
oped to allow comparison of non-compliance costs.
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OBJECTIVES: To explore whether discrepancies in values for
health states exist between the general population (healthy
people) and people who actually experience illness (patients).
It was hypothesized that the more elementary measurement
methods are, the more similar the responses of patients and
healthy people would be. This means that standardization of
own assessments supplemented with comparative judgment
would largely eliminate differences. METHODS: A sample of the
general population (n = 298) and two patient groups (rheuma-
toid arthritis, n = 27; cancer, n = 48) assessed the same 17 hypo-
thetical health states in an experimental setting. Patients did not
know that a description of their own health status was added to
the set of states. The ﬁrst and most elementary measurement
strategy consisted of ranking the health states, which can be
considered a step-by-step paired comparison task. In addition,
we used a multi-item visual analogue scale (VAS). This assess-
ment task can be considered as ranking supplemented with
adjusting the distances between the array of states in such a way
that the positions reﬂect the differences in preferences for these
states. The third measurement strategy was the time trade-off
(TTO) elicitation technique. RESULTS: Except for some moder-
ate divergence for certain health states, no overall differences
were found between patients and healthy people for the ranking
task or for the VAS. The TTO values, however, showed substan-
tially higher patient values (>0.20) for almost all moderate and
severe health states. This was more profound for the chronic
group of rheumatoid arthritis patients. CONCLUSIONS:
Patients’ assessment of health states are similar to assessments
of the general population when these are made by elementary
measurement methods. Therefore, valuation techniques based on
simple judgmental tasks such as ranking or discrete choices may
be better suited for deriving valid value-based health states.
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OBJECTIVES: The use of electronic patient reported outcomes
(ePRO) within clinical trials has grown rapidly with the increas-
ing acknowledgement by regulatory authorities that ePRO is an
acceptable method and one that directly addresses many of the
limitations of paper PROs. METHODS: A study of the charac-
teristics of ePRO use in clinical drug trials was undertaken to
understand the breath of therapeutic areas in which ePRO is
being used as well as to understand the dimensions affecting
compliance with ePRO. A dataset of 136 clinical trials was
analyzed by using ﬁelds that describe each protocol’s key
elements including ePRO instrument, Phase, Therapeutic Area,
Disorder and mean and median compliance broken down by
age deciles. RESULTS: The analysis determined that CNS (56
studies) and gastrointestinal disorders (21) represented 42% and
15% of ePRO use by the biopharmaceutical industry for this
dataset. Within CNS, ePRO was used heavily in depression
(24.3%), insomnia (9.6%) and anxiety protocols (8.1%).
Overall, ePRO was used in 16 different major disorders and
therapeutic areas. 57% of the time a named PRO instrument is
used electronically; the balance of the instruments is diaries or
symptom questionnaires which may not have undergone formal
validation. A sub-analysis of 8 pain studies representing 6% of
the studies showed that, with one exception, patients 46 years of
age and older are signiﬁcantly (means of 81.6% vs. 72.5%) more
compliant than study subjects younger than 46 years. The
median compliance for patients 66 of age and older was 87%.
CONCLUSIONS: This research shows that ePRO use within
clinical trials is both broad and deep; that patients can be highly
compliant; and that elderly patients are more compliant. Limita-
tions of this study include the clinical trials of this dataset which
can not be necessarily generalized as representative of all
ePRO use.
PMC44
THE SIGNIFICANCE OF PATIENT-REPORTED
OUTCOMESTO FACILITATE MARKET ACCESS DURING A
PRODUCT LIFECYCLE
Rofail D1,Abetz L1, Heelis R1, Brown C2
1Mapi Values, Bollington, UK, 2Mapi Values France, Lyon, France
OBJECTIVES: To demonstrate the signiﬁcance of patient-
reported outcomes (PROs) in facilitating market access using
evidence from deferasirox for iron-overload. METHODS:
Reviews of European reimbursement (NICE/French Transpar-
ency Commission) and regulatory authority (EMEA/CHMP)
guidance and opinions were performed. A PUBMED search was
implemented using PRO keywords and iron chelation therapy
(ICT). We considered the added value of deferasirox (oral-ICT)
demonstrated by PROs at various timepoints of the product
lifecycle. RESULTS: PROs in a product lifecycle can address
market access stakeholders’ concerns by demonstrating: 1)
disease/treatment burden on patients, and its impact on adher-
ence; 2) clinically meaningful outcomes from clinical trials and
beneﬁt to clinical practice; and 3) patient-perceived beneﬁts over
current treatments that may increase adherence, potentially
reducing health care costs. In our example, 28 studies were
identiﬁed. Medical importance and unmet needs were
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